Fulcrum Therapeutics, Inc. Logo

Fulcrum Therapeutics, Inc.

Develops gene-modulating small molecule drugs for rare, genetically defined diseases.

FULC | US

Overview

Corporate Details

ISIN(s):
US3596161097
LEI:
Country:
United States of America
Address:
26 LANDSDOWNE STREET, 2139 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for genetically defined rare diseases in areas of high unmet medical need. The company leverages its proprietary product engine to identify drug targets that can modulate gene expression to treat the known root cause of a disease. Fulcrum's primary focus is on discovering and developing small molecule drugs designed to be disease-modifying. Its patient-centered approach aims to create therapies that can transform the lives of patients and their caregivers by addressing the underlying genetic drivers of their conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Fulcrum Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fulcrum Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fulcrum Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany MYNZ
MAINZ BIOMED N.V. Logo
Develops molecular genetic diagnostic tests for early colorectal cancer detection in the US & Europe.
United States of America MYNZ

Talk to a Data Expert

Have a question? We'll get back to you promptly.